Loading
Nanoparticle-based Drug Delivery / Nanoplatforms for Cancer Theranostics · Journal article
Journal of Nanobiotechnology · August 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical proof-of-concept report describing engineering of a PSMA-targeted nitric oxide-releasing nanoparticle designed to penetrate solid tumors and sensitize DNA repair pathways. The work combines mechanistic cell biology with in vivo xenograft studies, but reports only qualitative outcomes ('strong tumor growth inhibition,' 'minimal systemic toxicity') without quantified efficacy metrics, comparators, or safety data.
Preclinical in vitro and in vivo proof-of-concept study. PSMA-positive prostate cancer cells (in vitro) and prostate cancer xenograft-bearing mice (in vivo). Intervention: NIR-activated PSMA-targeted nanomotors (M/B@PDA-VHH) releasing NO and ML216 under near-infrared irradiation.
NO generation from nanoparticles propels nanomotor movement and improves transport across endothelial barriers and penetration into 3D tumor spheroids and PCa tissues in vivo Photothermal/NO treatment induces DNA damage and promotes apoptosis; ML216 inhibits BLM helicase, causing replication fork stalling and accumulation of double-strand breaks ML216 suppresses AKT/mTOR signaling via dephosphorylation of p-AKT and p-PRAS40, disrupting DNA repair and amplifying oxidative damage
No quantified effect sizes, tumor growth inhibition percentages, survival data, or safety metrics reported Animal model xenograft is surrogate; clinical efficacy, pharmacokinetics, and tolerability unknown
This represents early-stage nanoparticle development without clinical validation. Researchers and clinicians should view this as a platform concept requiring substantial further development, safety characterization, and ultimately clinical translation before any therapeutic relevance can be assessed.
Preclinical proof-of-concept study in cell and animal models demonstrating a novel nanoparticle platform, without clinical efficacy data, controlled comparators, or quantified effect sizes.
As stated by the source record.
This represents early-stage nanoparticle development without clinical validation. Researchers and clinicians should view this as a platform concept requiring substantial further development, safety characterization, and ultimately clinical translation before any therapeutic relevance can be assessed.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Photothermal therapy (PTT) for solid prostate cancer (PCa) is often limited by poor intratumoral penetration and rapid DNA repair. Herein, we engineered a PSMA-targeted gas nanomotor that couple deep tumor penetration with DNA repair sensitization for enhanced photothermal/NO therapy. BLM helicase inhibitor ML216 and nitric oxide donor BNN6 were co-encapsulated with phase-change material and loaded into single-pore hollow polydopamine nanoparticles, followed by surface conjugation with anti-PSMA nanobodies (VHH) to yield M/B@PDA‑VHH NPs. VHH-mediated recognition confers active targeting toward PSMA-positive PCa cells. Under near-infrared irradiation, the nanoparticles show high photothermal conversion and trigger on-demand release of NO and ML216. NO generation propels nanomotor movement, markedly improving transport across endothelial barriers, penetration into 3D tumor spheroids, and distribution in PCa tissues in vivo. Photothermal/NO treatment induces DNA damage and promote apoptosis. Released ML216 inhibits BLM helicase, leading to replication fork stalling and accumulation of double-strand breaks, and concomitantly suppresses AKT/mTOR signaling via dephosphorylation of p‑AKT and p‑PRAS40. These effects disrupt DNA repair and amplify oxidative damage, restoring therapeutic sensitivity. In vitro and in vivo studies show strong tumor growth inhibition with minimal systemic toxicity. This gas-propelled platform offers a strategy to overcome stromal barriers and resistance in solid PCa.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.